TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Vendors in the pharmaceutical industry

Vendors in the pharmaceutical industry

Vendor Management

The use of external vendors in the pharmaceutical industry can often provide a cost-effective mechanism for increasing operational efficiency and productivity for an organisation. Pharmaceutical companies regularly engage with external vendors for the provision of a variety of services and materials that can be used throughout the product lifecycle from product development right through to commercial distribution.

However, while companies can delegate aspects of their operations to external vendors via contractual agreements, they cannot delegate responsibility and must continue to ensure that the quality of the products and services they receive are appropriate.  Annex 16 of the EU Guidelines for GMPs “Certification by a Qualified Person and Batch Release” outlines that the  Marketing Authorisation Holder (MAH) is responsible for the safety, quality and efficacy of a medicinal product and must have full oversight of their supply chain with sufficient controls in place to ensure that products are manufactured and distributed with GMP and GDP requirements. This can be further viewed by clicking on the following link; EU GMP Annex 16 . Similarly, ICH Q10 “Pharmaceutical Quality System” states that all companies, virtual or otherwise, are ultimately responsible for the products they place on the market. This guideline can be viewed at the following link; ICH Q10.

Selection of an appropriate vendor and periodic evaluation of the vendor is therefore a critical stage in the product lifecycle to ensure consumer demands for high quality products are met while also meeting high regulatory standards. PharmaLex have supported many organisations in the development of vendor management programmes and tailored these to match the business needs of individual organisations.  By having a robust vendor management programme in place, an organisation can benefit in one or all of the following areas:

  1. Improved Vendor Selection: The vendor selection process should consider items such as capacity, contingency planning and vendor capability. Once selected, vendors should be classified according to their level of risk or importance on the quality, safety and efficacy of the final product.
  2. Mitigate Risk: A formal assessment of the vendor quality system is required once the short-list of vendors is determined, to establish if the vendor has sufficient evidence of control over their internal processes. The level of assessment should be commensurate to the risk level applied to the vendor and once the risks are identified the necessary steps can be taken to mitigate against these risks. For non-critical vendors, the quality assessment may be limited to a specific section of the vendor questionnaire and /or the provision of an ISO 9001 or equivalent certificate whereas for vendors which are higher risk and provide critical materials/services, an onsite audit should be performed.
  3. Vendor Due Diligence: The performance of audits, vendor questionnaires, bona fides checks are examples of the types of due diligence checks that are used to ensure potential vendors are capable of successfully meeting your organisation’s needs.
  4. Optimise Efficiency: Having vendor management procedures and processes in place allows vendors to be onboarded and utilised more efficiently. In addition, the categorisation of vendors according to their level of risk allows you to determine the level of oversight required for each vendor. High risk vendors require more stringent oversight than that of low risk vendors.
  5. Consistency in the quality of materials or services received: Establishing contractual Quality and Technical Agreements where responsibilities, expectations and processes are outlined can help ensure the supply of materials/ services are fit for purpose.
  6. Optimise Performance: Once Key Performance Indicators (KPIs) are established and communicated to a vendor, monitoring the KPIs will allow your organisation to identify the strengths of a vendor and where improvement is required. Examples of KPIs may include complaints, OOS results, rejected batches.

Whether you are seeking support with the development of a vendor management process or are seeking to outsource the vendor management oversight element(s) of your organisation our experienced experts are here for you. PharmaLex have built up a wealth of expertise over the years and have a proven record of the ability to deliver in line with their company tagline “Confidence beyond Compliance”. Why not get in touch to find out more on the range of services that we offer by connecting with us on +353 1 846 4742 or email us at contactirl@pharmalex.com.

Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We really appreciate your responsiveness and availability during our previous exchanges and it is what we are waiting for from our partner.

    Small Medium Sized Company, UK
    Head of Regulatory Affairs
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for